Lexicon Pharmaceuticals Named One of the Best Places to Work by The Scientist
May 15 2007 - 7:30AM
PR Newswire (US)
Lexicon in Top 15 of Best Life Sciences Companies Worldwide THE
WOODLANDS, Texas, May 15 /PRNewswire-FirstCall/ -- Lexicon
Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that it has
been named by The Scientist as one of the "Best Places To Work in
Industry." "This is the fourth year running in which The Scientist
has named our firm one of the Best Places to Work in Industry,"
said Arthur T. Sands, M.D., Ph.D., Lexicon's president and chief
executive officer. "The talent and dedication of our employees is
the cornerstone of Lexicon's success and we strive daily to make
Lexicon a positive, innovative, supportive place to work. We salute
our employees' passion for science and our mission of bringing
breakthrough treatments to market." The Scientist, a life sciences
industry magazine, received responses to its 5th annual survey from
248 life sciences companies worldwide. Respondents were asked to
assess their working environment according to 45 criteria in
categories including internal communications, quality of the
research environment and opportunities for training and
development. Based on these survey responses, The Scientist
compiled a list of the top 15 large and small companies in which to
work. The Scientist's May issue, available in print and online,
features detailed survey results and rankings. About Lexicon
Lexicon is a biopharmaceutical company focused on the discovery and
development of breakthrough treatments for human disease. Lexicon
currently has clinical programs underway for such areas of major
unmet medical need as irritable bowel syndrome and cognitive
disorders. The company has used its proprietary gene knockout
technology to discover more than 100 promising drug targets and
create an extensive pipeline of clinical and preclinical programs
in the therapeutic areas of diabetes and obesity, cardiovascular
disease, psychiatric and neurological disorders, cancer, immune
system disorders and ophthalmic disease. To advance the development
and commercialization of its programs, Lexicon is working both
independently and through collaborators including Bristol-Myers
Squibb Company, Genentech, Inc., N.V. Organon and Takeda
Pharmaceutical Company Limited. For additional information about
Lexicon and its programs, please visit http://www.lexpharma.com/.
Safe Harbor Statement This press release contains "forward-looking
statements," including statements relating to Lexicon's growth and
future operating results, discovery and development of products,
strategic alliances and intellectual property, as well as other
matters that are not historical facts or information. All
forward-looking statements are based on management's current
assumptions and expectations and involve risks, uncertainties and
other important factors, specifically including those relating to
Lexicon's ability to successfully conduct preclinical and clinical
development of its potential drug candidates, advance additional
candidates into preclinical and clinical development, obtain
necessary regulatory approvals, achieve its operational objectives,
obtain patent protection for its discoveries and establish
strategic alliances, as well as additional factors relating to
manufacturing, intellectual property rights, and the therapeutic or
commercial value of its drug candidates, that may cause Lexicon's
actual results to be materially different from any future results
expressed or implied by such forward-looking statements.
Information identifying such important factors is contained under
"Factors Affecting Forward-Looking Statements" and "Risk Factors"
in Lexicon's annual report on Form 10-K for the year ended December
31, 2006, as filed with the Securities and Exchange Commission.
Lexicon undertakes no obligation to update or revise any such
forward-looking statements, whether as a result of new information,
future events or otherwise. DATASOURCE: Lexicon Pharmaceuticals,
Inc. CONTACT: Bobbie Faulkner, Manager, Investor Relations of
Lexicon, +1-281-863-3503, Web site: http://www.lexpharma.com/
Copyright
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Jul 2023 to Jul 2024